Levodopa/Benserazide Pch (Benserazide Hydrochloride, Levodopa)

Levodopa serves as a precursor that is converted to dopamine within the central nervous system, restoring deficient neurotransmitter activity. Benserazide inhibits peripheral decarboxylation of levodopa, ensuring more of the drug reaches the brain and reducing peripheral side effects.

The appropriate dose is individualized and determined by the prescribing clinician based on disease severity, patient response, and tolerability. Dosage adjustments are made during treatment to achieve optimal symptom control while minimizing adverse effects.

Safety data are limited, and the drug is generally not recommended for use during pregnancy or lactation unless the potential benefit justifies the risk. Physicians should evaluate each case carefully and discuss possible alternatives with the patient.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Levodopa/Benserazide is considered the most effective symptomatic therapy for Parkinson's disease because it directly replenishes dopamine. Compared with dopamine agonists, it often provides stronger motor improvement but may have a higher risk of dyskinesia. The combination with benserazide reduces peripheral side effects relative to levodopa alone.

The product should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the tablets in a dry place and out of reach of children.

Levodopa/Benserazide is taken orally, usually with a glass of water. It may be administered with or without food, but high‑protein meals can interfere with absorption, so clinicians often advise spacing the dose from protein‑rich meals.

Serious risks include severe psychiatric reactions such as hallucinations or psychosis, sudden severe hypotension, dyskinesia that can become disabling, and rare neuroleptic‑malignant‑like syndrome. Patients should be monitored closely for these events, especially during dose changes.

Patients with known hypersensitivity to levodopa, benserazide, or any excipients should avoid the medication. It is also contraindicated in individuals taking non‑selective MAO inhibitors or those with a history of malignant neuroleptic syndrome. Caution is advised in severe hepatic or renal impairment.